| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
|
Lancet Oncol
|
2012
|
6.09
|
|
2
|
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
|
Eur Urol
|
2013
|
4.89
|
|
3
|
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.
|
Eur Urol
|
2010
|
4.45
|
|
4
|
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).
|
Eur Urol
|
2004
|
3.72
|
|
5
|
Systematic review of complications of prostate biopsy.
|
Eur Urol
|
2013
|
3.66
|
|
6
|
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
|
Eur Urol
|
2013
|
3.34
|
|
7
|
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
|
Eur Urol
|
2012
|
3.30
|
|
8
|
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.
|
J Urol
|
2012
|
3.01
|
|
9
|
Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England.
|
Int J Urol
|
2014
|
2.72
|
|
10
|
Characterizing clinically significant prostate cancer using template prostate mapping biopsy.
|
J Urol
|
2011
|
2.61
|
|
11
|
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.
|
BJU Int
|
2010
|
2.59
|
|
12
|
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
|
BJU Int
|
2013
|
2.44
|
|
13
|
MR to ultrasound registration for image-guided prostate interventions.
|
Med Image Anal
|
2010
|
2.07
|
|
14
|
How good is MRI at detecting and characterising cancer within the prostate?
|
Eur Urol
|
2006
|
2.07
|
|
15
|
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
|
Eur Urol
|
2012
|
2.05
|
|
16
|
Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer.
|
J Urol
|
2012
|
1.99
|
|
17
|
Is it time to consider a role for MRI before prostate biopsy?
|
Nat Rev Clin Oncol
|
2009
|
1.87
|
|
18
|
The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.
|
BJU Int
|
2010
|
1.74
|
|
19
|
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery.
|
J Clin Epidemiol
|
2006
|
1.73
|
|
20
|
Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy.
|
BJU Int
|
2006
|
1.68
|
|
21
|
Self management for men with lower urinary tract symptoms: randomised controlled trial.
|
BMJ
|
2006
|
1.66
|
|
22
|
Photodynamic therapy for prostate cancer--a review of current status and future promise.
|
Nat Clin Pract Urol
|
2009
|
1.62
|
|
23
|
Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer.
|
BJU Int
|
2007
|
1.61
|
|
24
|
A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin.
|
BJU Int
|
2004
|
1.60
|
|
25
|
Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms.
|
J Urol
|
2003
|
1.58
|
|
26
|
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
|
BJU Int
|
2011
|
1.54
|
|
27
|
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment.
|
BMJ
|
2004
|
1.54
|
|
28
|
Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.
|
J Urol
|
2002
|
1.51
|
|
29
|
The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms.
|
Eur Urol
|
2007
|
1.51
|
|
30
|
The influence of family history on prostate cancer risk: implications for clinical management.
|
BJU Int
|
2010
|
1.48
|
|
31
|
A description of radical nephrectomy practice and outcomes in England: 1995-2002.
|
BJU Int
|
2005
|
1.46
|
|
32
|
Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment.
|
Arch Esp Urol
|
2010
|
1.44
|
|
33
|
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard.
|
Radiology
|
2013
|
1.39
|
|
34
|
Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants.
|
Nucl Med Commun
|
2015
|
1.39
|
|
35
|
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
|
BJU Int
|
2011
|
1.37
|
|
36
|
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.
|
Crit Rev Oncol Hematol
|
2010
|
1.34
|
|
37
|
Will focal therapy become a standard of care for men with localized prostate cancer?
|
Nat Clin Pract Oncol
|
2007
|
1.31
|
|
38
|
A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures.
|
J Urol
|
2004
|
1.31
|
|
39
|
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
|
Lancet Oncol
|
2012
|
1.18
|
|
40
|
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?
|
J Magn Reson Imaging
|
2012
|
1.18
|
|
41
|
The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation.
|
J Urol
|
2012
|
1.17
|
|
42
|
MR imaging of prostate after treatment with high-intensity focused ultrasound.
|
Radiology
|
2008
|
1.15
|
|
43
|
Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study.
|
Cancer
|
2012
|
1.11
|
|
44
|
Modelling prostate motion for data fusion during image-guided interventions.
|
IEEE Trans Med Imaging
|
2011
|
1.08
|
|
45
|
Mortality in men admitted to hospital with acute urinary retention: database analysis.
|
BMJ
|
2007
|
1.08
|
|
46
|
The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy.
|
BJU Int
|
2008
|
1.07
|
|
47
|
Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.
|
BJU Int
|
2010
|
1.06
|
|
48
|
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.
|
BJU Int
|
2012
|
1.05
|
|
49
|
Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England.
|
J Urol
|
2006
|
1.04
|
|
50
|
A biomedical engineering approach to mitigate the errors of prostate biopsy.
|
Nat Rev Urol
|
2012
|
1.02
|
|
51
|
Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™).
|
BJU Int
|
2011
|
1.01
|
|
52
|
The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management.
|
BJU Int
|
2005
|
1.00
|
|
53
|
To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
|
BJU Int
|
2006
|
0.99
|
|
54
|
Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study.
|
Urol Int
|
2011
|
0.98
|
|
55
|
The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers.
|
BJU Int
|
2008
|
0.98
|
|
56
|
A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy.
|
BJU Int
|
2012
|
0.97
|
|
57
|
Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach.
|
Eur Urol
|
2004
|
0.97
|
|
58
|
An analysis of the Research Fellowship Scheme of the Royal College of Surgeons of England.
|
J Am Coll Surg
|
2005
|
0.97
|
|
59
|
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
|
BJU Int
|
2005
|
0.97
|
|
60
|
Can MRI replace serial biopsies in men on active surveillance for prostate cancer?
|
Curr Opin Urol
|
2014
|
0.94
|
|
61
|
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
|
BJU Int
|
2006
|
0.94
|
|
62
|
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
|
BJU Int
|
2008
|
0.94
|
|
63
|
Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system.
|
BJU Int
|
2013
|
0.94
|
|
64
|
Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies.
|
Curr Urol Rep
|
2014
|
0.93
|
|
65
|
MRI-targeted prostate biopsy: a review of technique and results.
|
Nat Rev Urol
|
2013
|
0.93
|
|
66
|
Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.
|
Surg Oncol
|
2009
|
0.92
|
|
67
|
A novel tissue engineered three-dimensional in vitro colorectal cancer model.
|
Acta Biomater
|
2013
|
0.91
|
|
68
|
Management of low risk prostate cancer: active surveillance and focal therapy.
|
Curr Opin Urol
|
2014
|
0.91
|
|
69
|
The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis.
|
BJU Int
|
2006
|
0.90
|
|
70
|
Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI.
|
Eur Radiol
|
2014
|
0.90
|
|
71
|
Active surveillance for low-risk prostate cancer.
|
Crit Rev Oncol Hematol
|
2012
|
0.89
|
|
72
|
Men and chronic illness: a qualitative study of LUTS.
|
J Health Psychol
|
2004
|
0.89
|
|
73
|
Men's experiences of having lower urinary tract symptoms: factors relating to bother.
|
BJU Int
|
2004
|
0.89
|
|
74
|
Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?
|
World J Urol
|
2008
|
0.88
|
|
75
|
Frequency volume charts should be used in men with lower urinary tract symptoms.
|
Int J Surg
|
2005
|
0.88
|
|
76
|
Threshold volumes for urological cancer surgery: a survey of UK urologists.
|
BJU Int
|
2004
|
0.87
|
|
77
|
The role of MRI in active surveillance of prostate cancer.
|
Curr Opin Urol
|
2013
|
0.87
|
|
78
|
[International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool].
|
Prog Urol
|
2004
|
0.86
|
|
79
|
Benchmarks for success in focal therapy of prostate cancer: cure or control?
|
World J Urol
|
2010
|
0.86
|
|
80
|
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
|
BJU Int
|
2014
|
0.86
|
|
81
|
Histological outcomes after focal high-intensity focused ultrasound and cryotherapy.
|
World J Urol
|
2015
|
0.86
|
|
82
|
Sonablate-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer.
|
Expert Rev Med Devices
|
2006
|
0.85
|
|
83
|
Role of alpha-blockers in type III prostatitis: a systematic review of the literature.
|
J Urol
|
2007
|
0.85
|
|
84
|
Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy.
|
BJU Int
|
2008
|
0.85
|
|
85
|
Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway.
|
Urol Oncol
|
2013
|
0.84
|
|
86
|
Lower urinary tract symptoms in men: self-perceptions and the concept of bother.
|
BJU Int
|
2005
|
0.84
|
|
87
|
Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy.
|
Cancer
|
2011
|
0.84
|
|
88
|
MR to ultrasound image registration for guiding prostate biopsy and interventions.
|
Med Image Comput Comput Assist Interv
|
2009
|
0.83
|
|
89
|
A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations.
|
Prog Biophys Mol Biol
|
2010
|
0.83
|
|
90
|
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
|
BJU Int
|
2009
|
0.83
|
|
91
|
Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series.
|
BJU Int
|
2011
|
0.82
|
|
92
|
The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review.
|
BJU Int
|
2006
|
0.82
|
|
93
|
Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer?
|
BJU Int
|
2005
|
0.81
|
|
94
|
Self-management for men with lower urinary tract symptoms.
|
Curr Urol Rep
|
2009
|
0.80
|
|
95
|
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
|
BJU Int
|
2006
|
0.80
|
|
96
|
Behaviour modification and benign prostatic hyperplasia: replacement for medications.
|
Curr Opin Urol
|
2010
|
0.80
|
|
97
|
Light penetration in the human prostate: a whole prostate clinical study at 763 nm.
|
J Biomed Opt
|
2011
|
0.80
|
|
98
|
An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
|
BJU Int
|
2007
|
0.79
|
|
99
|
Focal therapy for prostate cancer: fact or fiction?
|
Urol Oncol
|
2010
|
0.79
|
|
100
|
The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy.
|
BJU Int
|
2006
|
0.79
|
|
101
|
Conceptual basis for focal therapy in prostate cancer.
|
J Endourol
|
2010
|
0.79
|
|
102
|
Re: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging: P. A. Pinto, P. H. Chung, A. R. Rastinehad, A. A. Baccala, Jr., J. Kruecker, C. J. Benjamin, S. Xu, P. Yan, S. Kadoury, C. Chua, J. K. Locklin, B. Turkbey, J. H. Shih, S. P. Gates, C. Buckner, G. Bratslavsky, W. M. Linehan, N. D. Glossop, P. L. Choyke and B. J. Wood J Urol 2011; 186: 1281-1285.
|
J Urol
|
2012
|
0.79
|
|
103
|
Tissue preservation may offer a harm-reduction strategy for men with early prostate cancer.
|
Eur Urol
|
2012
|
0.79
|
|
104
|
Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer.
|
Int J Urol
|
2013
|
0.79
|
|
105
|
A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration.
|
BJU Int
|
2006
|
0.78
|
|
106
|
Biopsy strategies for selecting patients for focal therapy for prostate cancer.
|
Curr Opin Urol
|
2014
|
0.78
|
|
107
|
Active surveillance: is there a need for better risk stratification at the outset?
|
J Clin Oncol
|
2010
|
0.78
|
|
108
|
ASA scores in the preoperative patient: feedback to clinicians can improve data quality.
|
J Eval Clin Pract
|
2007
|
0.78
|
|
109
|
Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.
|
BJU Int
|
2012
|
0.78
|
|
110
|
Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI.
|
Eur Radiol
|
2015
|
0.78
|
|
111
|
Changes in patient characteristics and outcomes for radical cystectomy in England.
|
BJU Int
|
2005
|
0.77
|
|
112
|
The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer.
|
BJU Int
|
2010
|
0.77
|
|
113
|
Progress in prostate cancer imaging.
|
Urol Oncol
|
2012
|
0.77
|
|
114
|
Focal therapy in prostate cancer: determinants of success and failure.
|
J Endourol
|
2010
|
0.77
|
|
115
|
Health technology assessment in evolution - focal therapy in localised prostate cancer.
|
Expert Rev Anticancer Ther
|
2014
|
0.77
|
|
116
|
Methodological considerations in assessing the utility of imaging in early prostate cancer.
|
Curr Opin Urol
|
2015
|
0.77
|
|
117
|
Is focal therapy the future for prostate cancer?
|
Future Oncol
|
2010
|
0.77
|
|
118
|
Will the attributes of multiparametric MRI permit the creation of a new approach to therapy?
|
Curr Opin Urol
|
2015
|
0.76
|
|
119
|
Screening for prostate cancer appears to work, but at what cost?
|
BJU Int
|
2009
|
0.76
|
|
120
|
Time to rethink PSA screening.
|
Arch Intern Med
|
2011
|
0.76
|
|
121
|
Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
|
Lasers Surg Med
|
2011
|
0.76
|
|
122
|
To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?
|
Curr Opin Urol
|
2006
|
0.76
|
|
123
|
Role of repeated prostatic massage in chronic prostatitis: a systematic review of the literature.
|
Urology
|
2008
|
0.76
|
|
124
|
What tumours should we treat with focal therapy based on risk category, grade, size and location?
|
Curr Opin Urol
|
2015
|
0.75
|
|
125
|
The relationship between volume and outcome in urological surgery.
|
BJU Int
|
2004
|
0.75
|
|
126
|
Behavioural approaches are helpful in overactive bladder.
|
BMJ
|
2003
|
0.75
|
|
127
|
Life after prostate cancer. Time to evaluate focal therapy.
|
BMJ
|
2010
|
0.75
|
|
128
|
Endoscopic ablation: Irreversible tide of technological advancement?
|
BMJ
|
2008
|
0.75
|
|
129
|
Development and Phantom Validation of a 3D-Ultrasound-Guided System for Targeting MRI-visible Lesions during Transrectal Prostate Biopsy.
|
IEEE Trans Biomed Eng
|
2016
|
0.75
|
|
130
|
Volume-mortality for cystectomy. Centralisation of cancer services vindicated.
|
BMJ
|
2010
|
0.75
|
|
131
|
Re: Giacomo Novara, Antonio Galfano, Vincenzo Ficarra and Walter Artibani. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur urol 2006;50:675-83.
|
Eur Urol
|
2006
|
0.75
|
|
132
|
A 3D in vitro cancer model as a platform for nanoparticle uptake and imaging investigations.
|
Small
|
2014
|
0.75
|
|
133
|
High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
|
BJU Int
|
2009
|
0.75
|
|
134
|
Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy.
|
BMJ
|
2012
|
0.75
|
|
135
|
Editorial comment: Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
|
BJU Int
|
2012
|
0.75
|
|
136
|
Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868.
|
J Urol
|
2011
|
0.75
|
|
137
|
Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
|
J Urol
|
2011
|
0.75
|
|
138
|
Are we ready for the new wave of focal therapy interventions for men with early prostate cancer?
|
BJU Int
|
2013
|
0.75
|
|
139
|
Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
|
J Urol
|
2008
|
0.75
|
|
140
|
The reliability of the frequency-volume chart in assessing lower urinary tract symptoms.
|
BJU Int
|
2007
|
0.75
|
|
141
|
The role of anticholinergic drugs in men with lower urinary tract symptoms.
|
Curr Opin Urol
|
2008
|
0.75
|
|
142
|
Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms?
|
Curr Opin Urol
|
2004
|
0.75
|
|
143
|
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
|
BJU Int
|
2006
|
0.75
|
|
144
|
Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
|
Nucl Med Commun
|
2017
|
0.75
|
|
145
|
A statistical motion model based on biomechanical simulations for data fusion during image-guided prostate interventions.
|
Med Image Comput Comput Assist Interv
|
2008
|
0.75
|
|
146
|
Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?
|
Nat Rev Clin Oncol
|
2017
|
0.75
|
|
147
|
A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer.
|
Curr Opin Urol
|
2015
|
0.75
|
|
148
|
The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures.
|
BJU Int
|
2009
|
0.75
|
|
149
|
The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men.
|
Curr Opin Urol
|
2017
|
0.75
|
|
150
|
Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms?
|
BJU Int
|
2005
|
0.75
|
|
151
|
Deciding the future of British urology.
|
BJU Int
|
2006
|
0.75
|
|
152
|
Prolonging survival in prostate cancer: chemotherapy will have an important role.
|
BJU Int
|
2005
|
0.75
|
|
153
|
Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
|
BJU Int
|
2011
|
0.75
|
|
154
|
Information booklets for men with localized prostate cancer need to be improved.
|
BJU Int
|
2006
|
0.75
|
|
155
|
Hormone therapy: a revolution in understanding prostate cancer.
|
Lancet Oncol
|
2008
|
0.75
|
|
156
|
When thinking of initiating medical therapy for lower urinary tract symptoms, ask about cataracts.
|
BJU Int
|
2005
|
0.75
|